Figure 1.
Figure 1. Irradiated DA1-3b/CXCL10 leukemic cells induce prophylactic and therapeutic immunity. (A-C) Vaccine experiments. C3H/Hej mice were vaccinated with 106 irradiated DA1-3b leukemic cells that had been transduced with CXCL10 (DA1-3b/CXCL10; •), IL-12 (DA1-3b/IL-12; ▿), or control empty plasmid (DA1-3b/Zeo; ▪), and the mice were subsequently challenged with (A) 104, (B) 105, or (C) 106 wild-type DA1-3b cells. (D-F) Therapeutic experiments. C3H/Hej mice were injected with (D) 104, (E) 105,or (F) 106 wild-type DA1-3b/cells. Three days later mice were given injections of irradiated DA1-3b/CXCL10, DA1-3b/IL12, or DA1-3b/Zeo leukemic cells. Data represent 30 mice/group in 3 separate experiments.

Irradiated DA1-3b/CXCL10 leukemic cells induce prophylactic and therapeutic immunity. (A-C) Vaccine experiments. C3H/Hej mice were vaccinated with 106 irradiated DA1-3b leukemic cells that had been transduced with CXCL10 (DA1-3b/CXCL10; •), IL-12 (DA1-3b/IL-12; ▿), or control empty plasmid (DA1-3b/Zeo; ▪), and the mice were subsequently challenged with (A) 104, (B) 105, or (C) 106 wild-type DA1-3b cells. (D-F) Therapeutic experiments. C3H/Hej mice were injected with (D) 104, (E) 105,or (F) 106 wild-type DA1-3b/cells. Three days later mice were given injections of irradiated DA1-3b/CXCL10, DA1-3b/IL12, or DA1-3b/Zeo leukemic cells. Data represent 30 mice/group in 3 separate experiments.

Close Modal

or Create an Account

Close Modal
Close Modal